Two doses of a Covid-19 vaccine greatly reduce the risk of long Covid, according to studies from the U.K. and Israel.
AURORA, CO - DECEMBER 15: Sara Berech holds a dose of the Johnson & Johnson COVID-19 vaccine before it is administered in a clinical trial on December 15, 2020 in Aurora, Colorado. The Johnson & Johnson vaccine is the only one of the leading candidates given a single dose and could be submitted for emergency use by late January. Michael Ciaglo is the photographer.
The U.K. Office for National Statistics found that people who had received a second dose of a Covid-19 vaccine at least two weeks before their first positive Covid test were less likely to self-report long Covid at least 12 weeks later.
There was no difference in the likelihood of long Covid between those who received the Oxford/AstraZeneca vaccine and those who did not.
A study by researchers at Bar-Ilan University in Israel found that Israelis who had received two doses of a Covid-19 vaccine were less likely to experience fatigue, headaches, weakness, and persistent muscle pain.
The preprint study was updated last week and was based on data from 959 Covid patients, 637 of whom werevaccinated, along with 2,437 people who were not.
The Israeli study found that people who had received two doses of the vaccine were not more likely to have long Covid symptoms than people who had not.
A study published Monday in the journal Cell found that people with circulating coronaviruses in their system and autoantibodies are more likely to have long Covid symptoms. There was a correlation between long Covid and type 2 diabetes. People with a pre-existing cough or heart disease are more likely to have a loss of smell or taste. The study looked at Covid-19 patients for two to three months after their initial diagnosis.
On Tuesday, Ayanna Pressley and Don Beyer sent a letter to the Centers for Disease Control and Prevention requesting a report of its findings on long Covid.
Live updates on the coronaviruses.
All Rights Reserved © 2024
